EWTX News & Analysis
2 articles
Market Mood
EWTX CMO sells $685k worth of Edgewise Therapeutics shares
The Chief Medical Officer (CMO) of Edgewise Therapeutics (EWTX) sold $685,000 worth of the company's stock. This transaction highlights insider trading activity within EWTX, which could be interpreted as a response to the company's current performance in the market. The sale may affect investor confidence and market perception of Edgewise Therapeutics. Insider stock sales can indicate potential concerns or changes in corporate strategy that investors should consider.
Read More
JPMorgan Raises Edgewise Therapeutics Price Target to $45 on Pipeline Confidence
JPMorgan increased the price target for Edgewise Therapeutics, Inc. (EWTX) from $34 to $45 while maintaining an Overweight rating. This reflects optimism regarding the EDG-7500 pipeline and the upcoming release of 12-week data in Q2 2026, which may impact the outlook for EDG-7500. Additionally, long-term results from a study on sevasemten showed that patients maintained stable functional abilities over 3.5 years. The company also plans to present data from the GRAND CANYON pivotal cohort in Q4 2026, potentially aiding in regulatory approval for sevasemten.
Read More